The company has developed iReveal software to provide automated and reproducible assessments of breast density, allowing to identify patients with reduced sensitivity to digital mammography due to dense breast tissue.
Using an advanced software program, iReveal is said to assess breast density based on the range of categories established by the American College of Radiology’s Breast Imaging Reporting and Data System (BI- RADS).
iCAD CEO Ken Ferry said: "The launch of iReveal is another example of iCAD’s commitment to meeting the ever-expanding needs of healthcare providers and patients in cancer detection and treatment.
"This solution offers a standardized breast density measurement that eliminates reader variability and classifies density using the same factors considered by experienced radiologists."
According to the firm, PowerLook AMP platform provides facilities to add a range of options in computer aided detection (CAD), lesion analysis tools, automated breast density assessments, quality assurance and resource planning functionality.
iCAD also provides Xoft Axxent Electronic Brachytherapy (eBx) System, which received FDA and CE mark approval for use anywhere in the body, including treatment of non-melanoma skin cancer, early-stage breast cancer and gynecological cancers.
